M&A Deal Summary

SI Group Acquires Addivant

On June 1, 2018, SI Group acquired chemicals company Addivant from SK Capital Partners

Acquisition Highlights
  • This is SI Group’s 3rd transaction in the Chemicals sector.
  • This is SI Group’s 3rd transaction in the United States.
  • This is SI Group’s 1st transaction in Connecticut.

M&A Deal Summary

Date 2018-06-01
Target Addivant
Sector Chemicals
Buyer(s) SI Group
Sellers(s) SK Capital Partners
Deal Type Merger

Target

Addivant

Danbury, Connecticut, United States
website
Addivant is a provider of a comprehensive portfolio of additives including antioxidants, antiozonants, inhibitors, polymer modifiers and UV stabilizers used by customers to improve the production and performance properties of polymers, plastics and rubbers. Addivant is headquartered in Connecticut and maintains a global footprint with 11 plants on five continents.

Search 192,349 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

SI Group

The Woodlands, Texas, United States

website


Category Company
Founded 1906
Sector Chemicals
DESCRIPTION

SI Group is a developer and manufacturer of performance additives and intermediates solutions for industrial and consumer goods. SI Group was founded in 1906 and is based in The Woodlands, Texas.


DEAL STATS #
Overall 3 of 3
Sector (Chemicals) 3 of 3
Type (Merger) 1 of 1
State (Connecticut) 1 of 1
Country (United States) 3 of 3
Year (2018) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-10-10 TPC Group - Key Raw Material Facility

houston, Texas, United States

TPC Group - Key Raw Material Facility includes an on-site terminal and manufacturing assets for nonene, tetramer, and other propylene derivatives. Nonene and tetramer are propylene oligomers, used as intermediates in the production of plasticizers, detergents, lube oil additives, antioxidants, and other performance products.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-07-23 SI Group - Industrial Resin Business

Rio Claro, Brazil

SI Group's Industrial Resin Business provides resin business and associated manufacturing sites in Rio Claro (Brazil), Ranjangaon (India), and Johannesburg (South Africa), as well as licensed technology and multiple tolling agreements globally.

Sell -

Seller(S) 1

SELLER

SK Capital Partners

New York, New York, United States

Investor Investor Investor Investor Investor

website


Category Private Equity Firm
Founded 2007
PE ASSETS 4.9B USD
Size Large
Type Sector Agnostic
DESCRIPTION

SK Capital Partners is a private investor in mature and middle-market companies located throughout North America. SK Capital focuses on companies with opportunities for substantial business improvement and strong growth prospects. The Firm looks to invest $100 to $200 million of equity in transactions valued up to $500 million. Prospective businesses typically generate $50 to $500 million in revenues and at least $100 million in EBITDA. Areas of interest include specialty materials, chemicals and healthcare. The Firm will consider a variety of transaction situations, including buyouts, recapitalizations, growth equity financings, and corporate carve-outs. SK Capital Partners was spun out of Arsenal Capital Partners and became independent in 2007. SK Capital Partners is based in New York City.


DEAL STATS #
Overall 3 of 13
Sector (Chemicals) 2 of 8
Type (Merger) 1 of 2
State (Connecticut) 1 of 1
Country (United States) 3 of 8
Year (2018) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-06-01 SI Group

The Woodlands, Texas, United States

SI Group is a developer and manufacturer of performance additives and intermediates solutions for industrial and consumer goods. SI Group was founded in 1906 and is based in The Woodlands, Texas.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-07-23 Cambrex Drug Product- Business Unit

Whippany, New Jersey, United States

Cambrex Drug Product's Business Unit is a technology-focused contract manufacturing business with differentiated applications and capabilities in solid, semi-solid and liquid dosage forms, with a particular focus on controlled substances. Cambrex Drug Product's Business Unit was established in 2006 and is based in Whippany, New Jersey.

Sell $425M